Abstract "Innovative compounds as diacylglycerol acyltransferase inhibitors" This invention relates to novel compounds which are acyl coenzyme inhibitors to: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation and to Its use in therapy alone or in combination with weight management therapies or other triglyceride reduction therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have benefit including but not limited to obesity, obesity-related disorders, genetics (type 1 hyperlipidemia, type 5) and acquired forms of disorders related to hypertriglyceridemia or hyperlipoproteinemia caused by, but not limited to, lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplantation) and other factors es (pregnancy, alcohol consumption), hyperlipoproteinemia, chylomicronemia, dyslepidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular effects, angina, excessive hair growth (including syndromes associated with hirsutism), nephrotic, fibrosis such as myocardial, renal and hepatic fibrosis, hepatitis c acne infection or other skin disorders.resumo “compostos inovadores como inibidores de diacilglicerol aciltransferase” esta invenção refere-se a compostos inovadores que são inibidores de acil coenzima a: diacilglicerol aciltransferase 1 (dgat-1), a composições farmacêuticas que contêm os mesmos, a processos para sua preparação e ao seu uso em terapia, sozinhos ou em combinação com terapias de gerenciamento de peso ou outras terapia de redução de triglicerídeo para a prevenção ou tratamento de doenças relacionadas à disfunção de dgat-1 ou em que a modulação da atividade de dgat-1 pode ter benefício terapêutico que inclui, mas não se limita a, obesidade, distúrbios relacionados à obesidade, genética (hiperlipidemia tipo 1, tipo 5) e formas adq
